1. Home
  2. FIHL vs EVO Comparison

FIHL vs EVO Comparison

Compare FIHL & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fidelis Insurance Holdings Limited

FIHL

Fidelis Insurance Holdings Limited

HOLD

Current Price

$19.26

Market Cap

2.0B

Sector

N/A

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$3.35

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FIHL
EVO
Founded
2014
1993
Country
Bermuda
Germany
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.1B
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
FIHL
EVO
Price
$19.26
$3.35
Analyst Decision
Hold
Strong Buy
Analyst Count
7
1
Target Price
$21.14
$7.00
AVG Volume (30 Days)
508.8K
253.2K
Earning Date
02-24-2026
11-05-2025
Dividend Yield
3.08%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,573,400,000.00
$887,396,457.00
Revenue This Year
$9.79
N/A
Revenue Next Year
$9.45
$8.52
P/E Ratio
N/A
N/A
Revenue Growth
11.89
N/A
52 Week Low
$14.17
$2.84
52 Week High
$19.83
$4.80

Technical Indicators

Market Signals
Indicator
FIHL
EVO
Relative Strength Index (RSI) 52.47 61.17
Support Level $19.24 $3.10
Resistance Level $19.76 $3.23
Average True Range (ATR) 0.42 0.08
MACD -0.02 0.04
Stochastic Oscillator 36.42 97.92

Price Performance

Historical Comparison
FIHL
EVO

About FIHL Fidelis Insurance Holdings Limited

Fidelis Insurance Holdings Ltd is a specialty insurer that leverages strategic partnerships to offer tailored insurance solutions. The company classifies its business into two segments, Insurance and Reinsurance. A majority of its revenue is generated from the Insurance segment, which comprises a portfolio of property, marine, aviation and aerospace, political risk, violence and terror, energy, cyber, and other insurance risks. The Reinsurance segment consists of an actively managed property reinsurance book, providing reinsurance and a limited amount of retrocession coverage across the world on a proportional or excess-of-loss basis. Geographically, the company derives its key revenue from the United Kingdom, followed by Bermuda and the Republic of Ireland.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: